MYRIAD GENETICS INC

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of and (unaudited)

Condensed Consolidated Balance Sheets (unaudited)

	September 30,2026	December 31,2025
ASSETS
Current assets:
Cash and cash equivalents	$107.1	$149.6
Trade accounts receivable	105.5	115.3
Inventory	28.6	30.6
Prepaid taxes	1.5	12.0
Prepaid expenses and other current assets	29.2	25.1
Total current assets	271.9	332.6
Operating lease right-of-use assets	48.9	49.4
Property, plant and equipment, net	104.7	114.0
Intangible assets, net	131.8	153.4
Goodwill	47.1	51.6
Other assets	4.8	5.6
Total assets	$609.2	$706.6
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$27.6	$30.0
Accrued liabilities	102.2	96.9
Current maturities of operating lease liabilities	7.8	6.9
Total current liabilities	137.6	133.8
Long-term debt	121.1	119.9
Noncurrent operating lease liabilities	80.5	83.0
Other long-term liabilities	1.0	1.9
Total liabilities	340.2	338.6
Commitments and contingencies
Stockholders’ equity:
Common stock, 95.7 and 93.5 shares outstanding at September 30, 2026 and December 31, 2025, respectively	1.0	0.9
Additional paid-in capital	1,511.2	1,489.0
Accumulated other comprehensive income	0.7	0.8
Accumulated deficit	(1,243.9)	(1,122.7)
Total stockholders' equity	269.0	368.0
Total liabilities and stockholders’ equity	$609.2	$706.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.